GLP1R and diabetes mellitus: Specifically, our data highlight the importance of monitoring renal function (eGFR and ACR), and considering the early use of renin-angiotensin system (RAS) inhibitors, sodium-glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly in patients with diabetes mellitus, in light of recent data demonstrating their ability to mitigate cardio-renal -metabolic risk.